Shimomura Akihiko, Shiino Sho, Kawauchi Junpei, Takizawa Satoko, Sakamoto Hiromi, Matsuzaki Juntaro, Ono Makiko, Takeshita Fumitaka, Niida Shumpei, Shimizu Chikako, Fujiwara Yasuhiro, Kinoshita Takayuki, Tamura Kenji, Ochiya Takahiro
Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Department of Medical Oncology and Translational Research, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Cancer Sci. 2016 Mar;107(3):326-34. doi: 10.1111/cas.12880. Epub 2016 Mar 4.
MicroRNA (miRNA), which are stably present in serum, have been reported to be potentially useful for detecting cancer. In the present study, we examined the expression profiles of serum miRNA in several large cohorts to identify novel miRNA that can be used to detect early stage breast cancer. We comprehensively evaluated the serum miRNA expression profiles using highly sensitive microarray analysis. A total of 1280 serum samples of breast cancer patients stored in the National Cancer Center Biobank were used. In addition, 2836 serum samples were obtained from non-cancer controls, 451 from patients with other types of cancers, and 63 from patients with non-breast benign diseases. The samples were divided into a training cohort including non-cancer controls, other cancers and breast cancer, and a test cohort including non-cancer controls and breast cancer. The training cohort was used to identify a combination of miRNA that could detect breast cancer, and the test cohort was used to validate that combination. miRNA expressions were compared between patients with breast cancer and non-breast cancer, and a combination of five miRNA (miR-1246, miR-1307-3p, miR-4634, miR-6861-5p and miR-6875-5p) was found to be able to detect breast cancer. This combination had a sensitivity of 97.3%, specificity of 82.9% and accuracy of 89.7% for breast cancer in the test cohort. In addition, this combination could detect early stage breast cancer (sensitivity of 98.0% for Tis).
据报道，稳定存在于血清中的微小RNA（miRNA）可能对癌症检测有用。在本研究中，我们检测了几个大型队列中血清miRNA的表达谱，以鉴定可用于检测早期乳腺癌的新型miRNA。我们使用高灵敏度微阵列分析全面评估血清miRNA表达谱。使用了存储在国家癌症中心生物样本库中的1280份乳腺癌患者血清样本。此外，还从非癌症对照者中获取了2836份血清样本，从其他类型癌症患者中获取了451份，从非乳腺良性疾病患者中获取了63份。样本被分为一个训练队列（包括非癌症对照者、其他癌症患者和乳腺癌患者）和一个测试队列（包括非癌症对照者和乳腺癌患者）。训练队列用于鉴定可检测乳腺癌的miRNA组合，测试队列用于验证该组合。比较了乳腺癌患者和非乳腺癌患者之间的miRNA表达，发现五种miRNA（miR-1246、miR-1307-3p、miR-4634、miR-6861-5p和miR-6875-5p）的组合能够检测乳腺癌。在测试队列中，该组合对乳腺癌的敏感性为97.3%，特异性为82.9%，准确性为89.7%。此外，该组合能够检测早期乳腺癌（Tis的敏感性为98.0%）。
